Variables of the fibrinolytic system: Risk indicators for CHD

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 1, 1997, Pages 47-49

  Juhan Vague, I ^a   Alessi, M C ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; GEMFIBROZIL; METFORMIN; NICOTINIC ACID;

ATHEROGENESIS; ATHEROSCLEROSIS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; EXERCISE; FIBRINOLYSIS; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

EID: 0030709424     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80022-7     Document Type: Conference Paper

References (12)

1. Juhan-Vague I, Alessi M C. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127-136.
2. Meade T W, Ruddock V, Stirling Y, Chakrabarti T, Miller G J. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
3. Thompson S G, Kienast J, Pyke S D M, Haverkate F, van de Loo J C W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
4. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
5. Gram J, Jespersen J, Kluft C, Rijken D C. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial infarction. Acta Med Scand 1987; 221: 149-153.
6. Jansson J H, Nilsson T K, Olofsson B O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-161.
7. Jansson J H, Olofsson B O, Nilsson T K Predictive value of value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7 year follow up. Circulation 1993; 88: 2030-2034.
8. Ridker P M, Vaughan D E, Stampfer M J, Manson J E, Hennekens C H. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
9. Juhan-Vague I, Alessi M C, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
10. Juhan-Vague I, Alessi M C, Joly P, Thirion X, Vague P, Declerck P J, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor 1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989; 9: 362-367.
11. Haverkate F, Thompson S G, Duckert F. Haemostasis factors in Angina Pectoris: Relation to gender, age and acute-phase reaction. Thromb Haemost 1995; 73: 561-567.
12. Julian-Vague I, Pyke S, Alessi M C, Jespersen J, Haverkate F, Thompson S G. Fibrinolytic factors and the risk of myocardial infaction or sudden death in patients with angina pectoris. Circulation 1996 (in revision).